Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
The purpose of this first-in-man study is to evaluate safety and tolerability of ODM-208 in patients with metastatic castration-resistant prostate cancer.
Prostate Cancer Metastatic
DRUG: ODM-208|DRUG: Midazolam
Maximum tolerated dose (MTD), Highest dose level at which under 33% of patients in a cohort experience DLT, Within first 28 days of treatment
Safety and tolerability profile of ODM-208 will be explored